Steve Cohen purchasing Pozen sharesVery positive sign.
Steve Cohen’s Point72 Asset Management New Position in POZEN Inc. (NASDAQ:POZN)
Point72 Asset Management has filled a SC 13G form regarding Pozen Inc Nc 6.40 +0.50 8.47%. Filing Link: 000089914016000961. Per Steve Cohen’s Point72 Asset Management’s filing, the filler now owns 5.2% of the Health Care-company, holding 1,691,343 shares.
POZEN Inc. (NASDAQ:POZN) is a newly disclosed equity position for the hedge fund and the filing was required due to activity on January 15, 2016. This most probably shows Steve Cohen’s Point72 Asset Management’s confidence and optimism in the future of the company.
The hedge fund has been active in the Health Care sector recently. In the fund’s latest 13F, it revealed several positions. This sector is 12% of Steve Cohen’s Point72 Asset Management’s US equities portfolio.
Pozen Inc Nc Hedge Funds Ownership
Latest SEC filings show 83 hedge funds and institutional investors own Pozen Inc Nc. The institutional ownership of the company in Q1 2015 is high, at 56.78 % of the shares outstanding. They increased by 256308 the total shares they hold. As of that quarter these institutional investors owned 18611678 shares. A total of 8 funds opened new positions in Pozen Inc Nc and 35 increased their holdings. There were 15 funds that closed their positions and 33 that reduced them.
Contrarius Investment Management Ltdis the most positive institutional investor on Pozen Inc Nc, with ownership of 677999 shares as of Q1 2015 for 0.42% of the fund’s portfolio. Paul Reeder And Edward Shapiro Par Capital Management Inc is another positive player owning 3863699 shares of the company or 0.69% of their stocks portfolio. CAAmericafirst Capital Management Llchave less than 0.01% of their stock portfolio invested in the stock for 75609. Further, Ariel Investments Llc disclosed it had purchased a stake worth 0.16% of the fund’s stock portfolio in the company. The MN Whitebox Advisors Llc was also a notable investor in the firm, owning 138797 shares. Pozen Inc Nc is 0.04% of the fund’s stock portfolio.
Company Profile
POZEN Inc. (POZEN) is a pharmaceutical company. The Company has entered into a license agreement with Sanofi US, for the commercialization of PA8140 and PA32540, now known as YOSPRALA 81/40 and 325/40 (aspirin / omeprazole delayed release tablets). The Company has developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet has been approved by the FDA for the acute treatment of migraine attacks with or without aura in adults. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. The Company is developing a combination of a PPI and aspirin in a single tablet intended to induce fewer gastrointestinal complications compared to an aspirin taken alone in patients at risk for developing aspirin associated gastric ulcers.